MD Anderson Cancer Center

Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes | PR Newswire | 7/7/2020

… year.” “Historically, no single oncogenic driver of AML and MDS has been known to impact the majority of patients,” said Dr. Guillermo Garcia-Manero , Chief, Section of Myelodysplastic Syndromes at the University of Texas MD Anderson Cancer Center . “Recent studies have changed this understanding. The long isoform of IRAK4, itself the result of specific genetic mutations, was recently discovered to be a driver of disease in over half the population …

Houston hospitals grapple with bed, crucial medicine shortages amid COVID-19 spike | Becker’s Hospital Review | 7/2/2020

… surgeries and had to transfer about a dozen patients who needed intensive care to other hospitals, the hospital said in a note to staff obtained by NBC News and ProPublica . The University of Texas MD Anderson Cancer Center also alerted employees that it would start admitting cancer patients with COVID-19 from public hospitals in the city. To view the full report, click here. More articles on public health …

Follow MD Anderson Cancer Center:    

New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model | PR Newswire | 7/1/2020

… 19-4092.full-text.pdf The study was performed by lead author Martina Ott , Ph.D., Instructor of Neurosurgery, senior author Amy Heimberger , M.D., professor of Neurosurgery, and a team of researchers at The University of Texas MD Anderson Cancer Center . Heimberger also is the Principle Investigator of the current investigator-initiated clinical trial of WP1066 for brain tumors. In the current study, C57BL/6 mice underwent intracerebral implantation of GL261 glioma cells …

CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design | PR Newswire | 6/30/2020

… to set the standard for innovative clinical trial design and analysis in the statistical and medical communities. Founder Dr. Don Berry is a professor in the Department of Biostatistics of The University of Texas MD Anderson Cancer Center and has designed and supervised the conduct of hundreds of clinical trials, including in glioblastoma, GBM-AGILE, and pancreatic cancer. As a result of his prolific experience in clinical design, he is …

University of Texas System and Medline to Enhance Supply Chain Strategy and Outcomes | PR Newswire | 6/29/2020

NORTHFIELD, Ill. Medline today announced a $120 million annual partnership with The University of Texas System Supply Chain Alliance . This award provides distribution services to the UT System’s three acute care institutions: UT Southwestern Medical Center in Dallas , UT MD Anderson Cancer Center in Houston , and UT Medical Branch in Galveston. Prior to choosing Medline as their MedSurg Distributor, the three institutions were using different distributors. Now, their distribution is …

University of Texas launches cancer data initiative | Becker’s Hospital Review | 6/26/2020

… Houston-based UTHealth is launching a collaborative cancer data initiative to combine oncology expertise with leading computational modeling strategies, the health system announced June 24. The initiative will be instituted at UTHealth’s Houston-based MD Anderson Cancer Center and two of its Austin-based engineering and computing centers. It aims to bring together oncology and data analytics teams to contextualize qualitative data and create better care solutions by sharing infrastructure …

Watch: From nose to toe, the Covid-19 virus attacks like no other ‘respiratory’ infection | STAT | 6/26/2020

… from head to toe came as a surprise to clinicians. Since “ACE2 is also the receptor for SARS, its expression in other organs and cell types has been well-known,” said Anirban Maitra of MD Anderson Cancer Center , who led a study mapping the receptor in cells of the GI tract. (Maitra is an expert in pancreatic cancer and, like many scientists this year, added Covid-19 to his research …

Sitting all day may increase your risk of dying from cancer | Deccan Herald | 6/26/2020

… also rarely examined whether and how occasional spurts of exercise might alter the risk equation. So, for the new study, which was published in June in JAMA Oncology, researchers at the University of Texas MD Anderson Cancer Center in Houston and other institutions around the country decided to re-examine data already collected as part of a large, nationwide study of risk factors for strokes. That study had enrolled a …

New US Patent Protects Key Element of First-in-Class Prodrug Candidate for Triple Negative Breast Cancer | 6/26/2020

… unit of OBDURO Biotechnologies. Under an aggregate $1.75MM grant from the DoD CDMRP Breast Cancer program, OBDURO business unit EnduRx is collaborating with Dr. Naoto Ueno’s breast cancer team at The University of Texas MD Anderson Cancer Center , Houston to develop a novel therapeutic for triple-negative breast cancer and advance it to the point of pre-IND meeting. The prodrug candidate utilizes the LinTT1 tumor-targeting peptide. “Triple negative …

Minimally Invasive Hysterectomy Tied to Worse Cervical Cancer Outcomes | 6/26/2020

… and death compared with open surgery among patients undergoing radical hysterectomy for early-stage cervical cancer, according to research published online June 11 in JAMA Oncology . Roni Nitecki, M.D., from The University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a systematic literature review to identify 49 studies comparing outcomes after minimally invasive (laparoscopic or robot-assisted) and open radical hysterectomy in patients with early-stage cervical …

Talzenna Patient-Reported Outcomes | 6/26/2020

Sign in to receive recommendations ( Learn more ) 00:00 Download Dr. Jennifer Litton, a board-certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is chief of the Section of Clinical Research and Drug Development for Breast Cancer. She also is a member of the Breast Immuno-Oncology Task Force of the National Cancer Institute. At the American …

Isaiah J. (Josh) Fidler, DVM, PhD, FAACR: In Memoriam (1936-2020) A Visionary Research Career Dedicated to Understanding the Complexities of Cancer Metastasis | 6/26/2020

… of the AACR Academy (2013), Fellowship of the American Association for the Advancement of Science (2007); and the American Society for Investigative Pathology Gold Headed Cane Award (2016). In his 36-year career at MD Anderson Cancer Center (1983–2019), the Institution honored him with the Ernst W. Bertner Memorial Award (1983), the Charles A. LeMaistre Outstanding Achievement Award (2004), the President’s Award together with his wife Margaret L. Kripke …

Sedentary Behavior and Risk of Cancer Mortality | 6/26/2020

… is the first study that definitively shows a strong association between not moving and cancer death,” said lead study author Susan Gilchrist, MD , Associate Professor of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center , in a statement. “Our findings show that the amount of time a person spends sitting prior to a cancer diagnosis is predictive of time to cancer death.” Study Design The study involved …

MD Anderson and UT Austin Create Unique Data-Driven Collaboration to Eliminate Cancer Using Novel Mathematical and Computational Approaches | 6/25/2020

AUSTIN, Texas — The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center (TACC) – have announced a new initiative to build a strong collaboration in oncological data and computational science. The collaboration between the three UT System institutions, based in Houston and Austin, will support the development of teams …

More Sedentary Time Tied to Higher Risk for Cancer Mortality | 6/25/2020

Print (HealthDay News) — Greater sedentary time is independently associated with a higher cancer mortality risk, according to a study published online in JAMA Oncology . Susan C. Gilchrist, MD, from The University of Texas MD Anderson Cancer Center in Houston, and colleagues examined associations between accelerometer-measured sedentary behavior (total volume and accrual in prolonged, uninterrupted bouts) and cancer mortality among 8002 black and white adults (45.8% male; mean age, 69.8 …

NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors | Business Wire | 6/25/2020

ROCKVILLE, Md.- NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced the first patient has been dosed at The University of Texas MD Anderson Cancer Center in the Phase 1b/2a clinical trial of NT-I7 (efineptakin alfa) in combination with KEYTRUDA®, a leading checkpoint inhibitor (CPI), for the treatment of patients with relapsed/refractory advanced solid tumors. “We’re very pleased to further progress this critically important …

MD Anderson and UT Austin Create Data-Driven Collaboration to Eliminate Cancer Using Mathematical and Computational Approaches | 6/25/2020

MD Anderson and UT Austin Create Data-Driven Collaboration to Eliminate Cancer Using Mathematical and Computational Approaches June 25, 2020 AUSTIN, Texas, June 25, 2020 — The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center (TACC) – have announced a new initiative to build a strong collaboration in oncological …

Clinical Challenges: HR+/HER2- Advanced Breast Cancer and CDK4/6 Inhibitors | 6/25/2020

… the question then becomes, what next? “These drugs have all been approved in the last 5 years, so the pace of progress has been very rapid,” Debu Tripathy, MD, of the University of Texas MD Anderson Cancer Center in Houston, told MedPage Today . “We haven’t had the chance to do large-scale randomized trials on patients who progress on CKD4/6 inhibitors. Currently, we don’t have a dedicated drug that we …

Aldevron Announces Agreement with Ziopharm Oncology for neoGMP® Production of Sleeping Beauty Plasmid DNA to Express TCRs for Treatment of Solid Tumors | Business Wire | 6/25/2020

… a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty -enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20200625005616/en/ CONTACT: Ellen Shafer Senior Director of Marketing and Communications 701.297.9256 KEYWORD: UNITED STATES …

Houston ICUs at 97 Percent Capacity as Texas Coronavirus Cases Break Records | 6/25/2020

… accounted for more than one-quarter of those occupancies. The TMC’s latest report incorporated ICU admission numbers from seven affiliate hospitals in the Houston area: CHI St. Luke’s Health, Harris Health System, Houston Methodist, MD Anderson Cancer Center , Memorial Hermann, Texas Children’s Hospital and University of Texas Medical Branch. The hospitals can collectively admit 1,330 ICU patients at regular capacity, when 70 to 80 percent of total beds are typically …

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML | 6/25/2020

… you use both things together” or in sequence. “You can look at it in both ways,” said lead investigator Courtney DiNardo, MD, associate professor in the department of leukemia at the University of Texas MD Anderson Cancer Center , Houston. “We do know” that with enasidenib monotherapy, there’s “a decrement in the rates of remission and in the duration of response” and overall survival in the salvage setting, so there’s “a …

AACR: Minority accrual in clinical trials is a team sport | 6/24/2020

… for us to fully be able to generalize the effects regarding the toxicity or efficacy or a medication,” said Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center . Though the US has almost 59 million Hispanic residents, representing 18% of the population, Hispanic participants represent fewer than 8% of clinical trial enrollees and fewer than 1% of those enrolled in …

Affimed Reports First Quarter 2020 Financial Results and Operational Progress | Globe Newswire | 6/23/2020

… and a good safety profile in the relevant pre-clinical models AFM13: Continued progress on the REDIRECT monotherapy study in pTCL as well as on the AFM13 combination with cbNk investigator sponsored study at MD Anderson Cancer Center in CD30-positive T cell lymphoma Management: Appointed Angus Smith as Chief Financial Officer, following the appointments of Dr. Andreas Harstrick as Chief Medical Officer and Dr. Arndt Schottelius as Chief Scientific …

Affimed Reports First Quarter 2020 Financial Results and Operational Progress Nasdaq:AFMD | Globe Newswire | 6/23/2020

… and a good safety profile in the relevant pre-clinical models AFM13: Continued progress on the REDIRECT monotherapy study in pTCL as well as on the AFM13 combination with cbNk investigator sponsored study at MD Anderson Cancer Center in CD30-positive T cell lymphoma Management: Appointed Angus Smith as Chief Financial Officer, following the appointments of Dr. Andreas Harstrick as Chief Medical Officer and Dr. Arndt Schottelius as Chief Scientific …

New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulin | Globe Newswire | 6/23/2020

… Phase 1 clinical trial in patients who failed or progressed on PD-1 / PD-L1 antibody treatments. Principal investigator Steven H. Lin, M.D., Ph.D., associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center , presented the research data. “The experiments from my lab demonstrated that Plinabulin treatment in murine cancer models leads to activation of antigen-presenting dendritic cells,” said Dr. Lin. “The combination therapy with …

Medical Research

Watch: From nose to toe, the Covid-19 virus attacks like no other ‘respiratory’ infection | STAT | 6/26/2020

… up at night,” said Thomas McGinn, deputy physician in chief at Northwell Health and director of the Feinstein Institutes for Medical Research. “It’s amazing how many different ways it affects the body.” Related: As Covid … cell types has been well-known,” said Anirban Maitra of MD Anderson Cancer Center, who led a study mapping the receptor in cells of the GI tract. (Maitra is an expert in pancreatic cancer and …

Patient Recruitment

Affimed Reports First Quarter 2020 Financial Results and Operational Progress | Globe Newswire | 6/23/2020

patient recruitment Data on Affimed’s AFM24 (EGFR/CD16A) and Genentech’s RO7297089 (BCMA/CD16A) was presented at AACR Virtual Meeting II, showing potent killing of tumor cell lines and a good safety profile in the relevant pre-clinical models AFM13: Continued progress on the REDIRECT monotherapy study in pTCL as well as on the AFM13 combination with cbNk investigator sponsored study at MD Anderson Cancer Center in CD30-positive T cell …

AACR

Affimed Reports First Quarter 2020 Financial Results and Operational Progress | Globe Newswire | 6/23/2020

AACR Virtual Meeting II, showing potent killing of tumor cell lines and a good safety profile in the relevant pre-clinical models AFM13: Continued progress on the REDIRECT monotherapy study in pTCL as well as on the AFM13 combination with cbNk investigator sponsored study at MD Anderson Cancer Center in CD30-positive T cell lymphoma Management: Appointed Angus Smith as Chief Financial Officer, following the appointments of Dr. Andreas Harstrick …

Radiotherapy

New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulin | Globe Newswire | 6/23/2020

… innovative immuno-oncology (I/O) therapies, today announced new preclinical research findings that indicate BeyondSpring’s lead asset, Plinabulin, enhances immuno-radiotherapy for cancer patients. The results of this preclinical study was highlighted in a poster … associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, presented the research data. “The experiments from my lab demonstrated that Plinabulin treatment in murine cancer models leads to activation of …

Hematology

ASH Announces 2020 Honorific Award Recipients | PR Newswire | 6/23/2020

WASHINGTON - The American Society of Hematology (ASH) congratulates this year’s recipients of the Honorific Awards, the Society’s most prestigious awards which recognize hematologists who have made significant contributions to the field. This year’s Honorific Award … Weill Cornell Medicine Courtney DiNardo , MD, The University of Texas MD Anderson Cancer Center Ernest Beutler Lecture and Prize Adolfo Ferrando , MD, PhD, Columbia University Genetics William Dameshek Prize Toshio Suda , MD, PhD, National University …

National Cancer Institute

DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II | PR Newswire | 6/22/2020

… 083’s new drug application (NDA) submission and registration. Dr. John de Groot , Chairman of the Department of Oncology at MD Anderson Cancer Center and planned Principal Investigator for the VAL-083 arm of the … head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on DelMar’s internal research programs and these prior NCI-sponsored clinical studies, DelMar is conducting clinical trials to support the …

American Society of Clinical Oncology

Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma | Globe Newswire | 6/22/2020

… expression, providing a compelling rationale for this combination. Recently, additional data from a phase 1 trial were presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting showing Controlled IL-12 in combination … partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com . Forward-Looking Statements Disclaimer This press release contains forward-looking statements as defined …

American Association for Cancer Research

Greater cfDNA Recovery May Help Accelerate Development of Cancer Liquid Biopsy Applications | PR Newswire | 6/22/2020

GARDEN GROVE, Calif. , June 22, 2020 /PRNewswire/ – PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific’s liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity. Early-stage cancer diagnostics and cancer screening applications …

Biotech

Greater cfDNA Recovery May Help Accelerate Development of Cancer Liquid Biopsy Applications | PR Newswire | 6/22/2020

GARDEN GROVE, Calif. , June 22, 2020 /PRNewswire/ – PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific’s liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity. Early-stage cancer diagnostics and cancer screening applications …

Cancer Therapy

DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II | PR Newswire | 6/22/2020

… and strong regulatory endorsement, is intended to serve as the basis for VAL-083’s new drug application (NDA) submission and registration. Dr. John de Groot , Chairman of the Department of Oncology at MD Anderson Cancer Center and planned Principal Investigator for the VAL-083 arm of the GCAR GBM AGILE registration study, noted, “These data continue to demonstrate an improvement over the historical outcomes of standard therapy and validate …

Oncology

DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II | PR Newswire | 6/22/2020

Oncology at MD Anderson Cancer Center and planned Principal Investigator for the VAL-083 arm of the GCAR GBM AGILE registration study, noted, “These data continue to demonstrate an improvement over the historical outcomes of standard therapy and validate VAL-083’s inclusion in a more robust setting as part of the GBM AGILE study. In MD Anderson’s Glioblastoma Moon Shots Program, we are looking to create giant leaps to …

Genomics

Bionano Genomics Reports First Quarter 2020 Financial Results and Provides Business Update | Globe Newswire | 6/18/2020

… Company to host conference call today, Thursday, June 18, at 4:30 pm ET June 18, 2020 16:01 ET Source: Bionano Genomics SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (NASDAQ: BNGO), a life … members Drs. Brynn Levy, Columbia University, and Rashmi Kanagal-Shamanna, MD Anderson Cancer Center, that also demonstrated 100% concordance between Bionano Genomics’ optical mapping technology and current gold standard cytogenetic methods in leukemia. Strengthened intellectual …

CAR-T

Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020 | Globe Newswire | 6/12/2020

CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com Investor Relations Contacts …

Gene Therapy

Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020 | Globe Newswire | 6/12/2020

… gene therapy, and rapidly manufactured Sleeping Beauty -enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com Investor Relations Contacts …

Digital Health

NCCN Policy Summit Explores 21st Century Cures Act and the Impact of Health Information Technology | Yahoo News | 6/10/2020

… Partners; Anobel Odisho , MD, MPH , Urologist , UCSF Helen Diller Family Comprehensive Cancer Center and Clinical Informatics Lead , UCSF Center for Digital Health Innovation; and Susan Stiles , MHA, MBA, FACHE , Executive, Oncology Business Unit , Cerner Corporation … NCCN Board Chair & Breast Medical Oncologist , The University of Texas MD Anderson Cancer Center . Drs. Allen and Walters presented recommendations for future policy improvements according to an NCCN working group of multidisciplinary experts from across …

Medical Education

Online Video Education Series from SITC and PlatformQ Health to Better Equip HCPs Managing Cancer Patients Undergoing Immunotherapy | PRWeb | 6/3/2020

… of Medicine, and Dr. Ignacio Wistuba, MD, Professor and Chair, Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. Dr. Herbst recently presented findings from a study showing profound benefits … PlatformQ Health Education is the leading provider of interactive digital medical education for clinicians, patients and caregivers. To improve patient care, PlatformQ Health Education creates video-first educational modules with premier partners, so learners can …

Patient Satisfaction

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

… standard revenue cycle benchmarks. The organizations have also implemented patient-centered recommendations from HFMA and have achieved high levels of patient satisfaction. Here are the 18 hospitals that received a 2020 MAP award, along with … St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners …

HFMA

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

The Healthcare Financial Management Association named its winners of the 2020 MAP Award for High Performance in Revenue Cycle. HFMA’s MAP award recognizes providers who surpassed standard revenue cycle benchmarks. The organizations have also implemented … St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners …

Healthcare Financial Management Association

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

The Healthcare Financial Management Association named its winners of the 2020 MAP Award for High Performance in Revenue Cycle. HFMA’s MAP award recognizes providers who surpassed standard revenue cycle benchmarks. The organizations have also implemented … St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners …

Food and Drug Administration

Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program | Globe Newswire | 6/1/2020

… author, Sapna Patel, MD, Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine of The University of Texas MD Anderson Cancer Center (MDACC), is also the lead principal investigator of this single-center … status has been granted to PV-10 by the U.S. Food and Drug Administration for the treatments of metastatic melanoma in 2006 , hepatocellular carcinoma in 2011 , neuroblastoma in 2018 , and ocular melanoma (including uveal melanoma …

Patient Safety

2 decades later: 50 best cancer hospitals in 2000 and 2020 | Becker’s Hospital Review | 5/28/2020

While Houston-based University of Texas MD Anderson Cancer Center and New York City-based Memorial Sloan Kettering Cancer Center have consistently battled for the No. 1 ranking over 20 years, U.S. News & World Report … measure in the analysis. Now the rankings factor several other patient safety indicators, including pressure ulcers and postoperative respiratory failure. For the most recent ranking, listed hospitals had to treat at least 227 Medicare inpatients …

NIH

NIAID Council Minutes - January 27, 2020 | National Institutes of Health | 5/28/2020

… MD Anderson Cancer Center. He takes over for Acting Commissioner Dr. Ned Sharpless, who returns to his previous position as director of the National Cancer Institute. Dr. Joshua Denny has been selected as CEO of the “All of Us” Research Program. As CEO, he will oversee NIH’s efforts to build one of the most comprehensive precision medicine research platforms in the world in partnership with a diverse network of awardees …

University of Utah

2 decades later: 50 best cancer hospitals in 2000 and 2020 | Becker’s Hospital Review | 5/28/2020

While Houston-based University of Texas MD Anderson Cancer Center and New York City-based Memorial Sloan Kettering Cancer Center have consistently battled for the No. 1 ranking over 20 years, U.S. News & World Report … 2020: Nebraska Medicine-Nebraska Medical Center (Omaha) No. 36 2000: University of Utah Hospitals and Clinics (Salt Lake City) 2020: Dan L. Duncan Comprehensive Cancer Center at Baylor St. Luke’s Medical Center (Houston) No. 37 …

UC Davis

2 decades later: 50 best cancer hospitals in 2000 and 2020 | Becker’s Hospital Review | 5/28/2020

While Houston-based University of Texas MD Anderson Cancer Center and New York City-based Memorial Sloan Kettering Cancer Center have consistently battled for the No. 1 ranking over 20 years, U.S. News & World Report … 28 2000: University of Wisconsin Hospital and Clinics (Madison) 2020: UC Davis Medical Center (Sacramento) No. 29 2000: Yale New Haven (Conn.) Hospital 2020: New York Presbyterian Hospital-Columbia and Cornell (New York City) No …

Credentialing

2 decades later: 50 best cancer hospitals in 2000 and 2020 | Becker’s Hospital Review | 5/28/2020

While Houston-based University of Texas MD Anderson Cancer Center and New York City-based Memorial Sloan Kettering Cancer Center have consistently battled for the No. 1 ranking over 20 years, U.S. News & World Report … recognition from external organizations like NCI and the American Nurses Credentialing Center). Magnet recognition was added as an indicator of structure in 2004. Some hospitals named in 2000 are no longer recognizable today, such as …

Moleculin Biotech

New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model | PR Newswire | 7/1/2020

HOUSTON Moleculin Biotech, Inc., (Nasdaq: MBRX ) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a peer-reviewed article … and a team of researchers at The University of Texas MD Anderson Cancer Center. Heimberger also is the Principle Investigator of the current investigator-initiated clinical trial of WP1066 for brain tumors. In the current …

Medline

University of Texas System and Medline to Enhance Supply Chain Strategy and Outcomes | PR Newswire | 6/29/2020

NORTHFIELD, Ill. Medline today announced a $120 million annual partnership with The University of Texas System Supply Chain Alliance . This award provides distribution services to the UT System’s three acute care institutions: UT Southwestern Medical Center in Dallas , UT MD Anderson Cancer Center in Houston , and UT Medical Branch in Galveston. Prior to choosing Medline as their MedSurg Distributor, the three institutions were using different distributors. Now, their distribution is …

Merck

NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors | Business Wire | 6/25/2020

… clinical-stage T cell-focused biopharmaceutical company, today announced the first patient has been dosed at The University of Texas MD Anderson Cancer Center in the Phase 1b/2a clinical trial of NT-I7 (efineptakin … or www.clinicaltrials.gov , identifier: NCT04332653 KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA. About NT-I7 NT-I7 (efineptakin alfa) is the only clinical-stage …

Merck & Co

NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors | Business Wire | 6/25/2020

… clinical-stage T cell-focused biopharmaceutical company, today announced the first patient has been dosed at The University of Texas MD Anderson Cancer Center in the Phase 1b/2a clinical trial of NT-I7 (efineptakin … registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA. About NT-I7 NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is …

Genentech

Affimed Reports First Quarter 2020 Financial Results and Operational Progress | Globe Newswire | 6/23/2020

… Genentech’s RO7297089 (BCMA/CD16A) was presented at AACR Virtual Meeting II, showing potent killing of tumor cell lines and a good safety profile in the relevant pre-clinical models AFM13: Continued progress on the REDIRECT monotherapy study in pTCL as well as on the AFM13 combination with cbNk investigator sponsored study at MD Anderson Cancer Center in CD30-positive T cell lymphoma Management: Appointed Angus Smith as Chief Financial Officer …

GSK

Is MIS for Gynecologic Cancer Resulting in Higher Recurrence and Mortality? | Physicians Weekly | 6/16/2020

… analysis of observational studies, Roni Nitecki, MD, from the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that patients undergoing MIS for early-stage … work. Karam reported receiving personal fees from Clovis Oncology, AstraZeneca, GSK, and UpToDate outside the submitted work. Dorigo reported receiving personal fees for advisory boards from Nektar, GSK/Tesaro, Myriad, Merck, Clovis, Personalized Adoptive Cell …

AstraZeneca

Gritstone Oncology Announces the Addition of Jean-Charles Soria, M.D., Ph.D., to its Scientific Advisory Board | Globe Newswire | 6/10/2020

… our co-founder Jean-Charles, a world-class medical oncologist and scientist, has rejoined our SAB following his tenure at AstraZeneca,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone … the department of thoracic head and neck medical oncology at MD Anderson Cancer Center, in Houston, USA, where he held an Adjunct Professorship from 2012 to 2017. Dr. Soria has contributed to over 640 peer …

Incyte

Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies | FierceBiotech | 6/9/2020

… Incyte, Eli Lilly, and the MD Anderson Cancer Center in partnering with the high-rising biotech, which in 2018 came into sharp focus when it raised $421 million in a Hong Kong IPO. Michael Yu, Ph.D., founder, chairman and CEO of Innovent, said: “Innovent first entered the cellular therapy space a few years ago, and with this partnership with Roche we are taking a much bolder step forward as we …

Eli Lilly

Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies | FierceBiotech | 6/9/2020

… Eli Lilly, and the MD Anderson Cancer Center in partnering with the high-rising biotech, which in 2018 came into sharp focus when it raised $421 million in a Hong Kong IPO. Michael Yu, Ph.D., founder, chairman and CEO of Innovent, said: “Innovent first entered the cellular therapy space a few years ago, and with this partnership with Roche we are taking a much bolder step forward as we build …

Gilead Sciences

Allogene, Servier’s ‘off-the-shelf’ CAR-T shows high response rate in Phase I lymphoma data at ASCO - MedCity News | 5/29/2020

… online due to Covid-19. Whereas the two CAR-T cell therapies currently on the market – Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel) are bespoke therapies made from patients’ own T cells, allogeneic … Dr. Sattva Neelapu, a hematologist at The University of Texas MD Anderson Cancer Center in Houston, said in a phone interview. With a median follow-up of 3.8 months, nine of 12 responding patients were …

Novartis

Allogene, Servier’s ‘off-the-shelf’ CAR-T shows high response rate in Phase I lymphoma data at ASCO - MedCity News | 5/29/2020

… which is taking place online due to Covid-19. Whereas the two CAR-T cell therapies currently on the market – Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel) are bespoke therapies made from patients … Dr. Sattva Neelapu, a hematologist at The University of Texas MD Anderson Cancer Center in Houston, said in a phone interview. With a median follow-up of 3.8 months, nine of 12 responding patients were …

Gilead

Allogene, Servier’s ‘off-the-shelf’ CAR-T shows high response rate in Phase I lymphoma data at ASCO - MedCity News | 5/29/2020

… online due to Covid-19. Whereas the two CAR-T cell therapies currently on the market – Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel) are bespoke therapies made from patients’ own T cells, allogeneic … Dr. Sattva Neelapu, a hematologist at The University of Texas MD Anderson Cancer Center in Houston, said in a phone interview. With a median follow-up of 3.8 months, nine of 12 responding patients were …

Exact Sciences

Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020 | PR Newswire | 5/29/2020

MADISON, Wis. Exact Sciences Corp. (NASDAQ: EXAS ) today announced it is presenting new data at the 2020 American Society of Clinical Oncology (ASCO20) Virtual Scientific Program. These data further demonstrate the clinical value of the … said Dr. Anthony Lucci , professor of Breast Surgical Oncology at MD Anderson Cancer Center. “Based on the new data presented at ASCO20, the Oncotype DX test identified women with a low likelihood of responding to …

Johnson & Johnson

Acquist Therapeutics Announces New Appointments to its Board of Directors | PR Newswire | 5/27/2020

… rare hereditary diseases. Dr. Haverty previously held leadership roles at Immusan T, Merck Research Labs, Schering-Plough Research Institute, and Johnson & Johnson’s Pharmaceutical Research Institutes. Dr. Haverty received a joint B.S. degree in Chemistry and … York . Subsequently, he was Assistant Professor of Medicine at the MD Anderson Cancer Center, Houston, TX. About Acquist Acquist has developed novel, potent, bifunctional inhibitors of enzymes that reduce production and promote excretion of uric …

IBM Watson

100 great hospitals in America | 2020 | Becker’s Hospital Review | 5/20/2020

… ranking and award agencies, including U.S. News & World Report ‘s 2019-20 rankings, CareChex, Healthgrades, CMS star ratings, Leapfrog grades and IBM Watson Health top hospitals. Becker’s also sought nominations for this list.This list was compiled … is known for its specialty services, which include the Baptist MD Anderson Cancer Center and robotic-assisted surgical procedures. In 2019-20, U.S. News & World Report ranked Baptist Medical Center Jacksonville the fifth best hospital in …

Bristol-Myers

SELLAS Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update | Globe Newswire | 5/14/2020

… of three members: Dr. Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, and Principal Investigator at MD Anderson for the multi-center Phase … an investigator-sponsored clinical trial of GPS in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, nivolumab (Opdivo ® ), in patients with MPM. In January 2020, SELLAS announced that it commenced patient screening for its …

Merck Research Laboratories

Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma | Business Wire | 5/14/2020

… HIF-2α in these patients who are in need of new options,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “These findings validate Merck’s long-term strategy for building the company’s oncology … Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. “The results of this study provide evidence of the potential benefit of MK-6482 and support further investigation into how this …

ImmunoGen

ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status | Business & Finance | heraldchronicle.com | Business Wire | 5/13/2020

WALTHAM, Mass.–(BUSINESS WIRE)–May 13, 2020– ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial data from the FORWARD II … Other CD123-Positive Hematologic Malignancies” Lead Author: Naval Daver, MD, MD Anderson Cancer Center Abstract: TPS7563 (Poster 336) Title: “A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 as Monotherapy or …

OrbiMed

Nucleix Strengthens Leadership and Expands Footprint for U.S. Growth of Liquid Biopsy Development | Business Wire | 5/11/2020

… MD Anderson Cancer Center, will join the company’s board. “More than 90 percent of individuals who qualify for lung cancer examinations do not receive annual screening as recommended in medical guidelines. 1 Providing an affordable blood test that screens these patients could increase compliance with imaging and help diagnose more patients early when survival rates are significantly higher,” said Erez Chimovits, partner at OrbiMed and lead investor of Nucleix. “Our …

Livongo Health

Lucid Lane has developed a service to get patients off of pain meds and avoid addiction | Yahoo News | 5/9/2020

… the new addiction prevention service Lucid Lane , was enjoying a successful career working as the founding chief technology officer at Livongo Health. It was the serial senior tech executive’s most recent job after a long … Hagberg, the chair of anesthesiology, perioperative and pain medicine of MD Anderson Cancer Center; and Sherif Zaafran, the president of the Texas Medical Board and chair of multiple national committees on pain management, including the …

Regeneron

Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update | Globe Newswire | 5/7/2020

… with FDA advance Ziopharm TCR-T IND process – – Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® ; Controlled IL-12 clinical data update at ASCO 2020 – – Work restrictions at NCI … make progress toward initiating our TCR-T clinical trial at MD Anderson Cancer Center based on the Sleeping Beauty platform and look forward to providing an update on the status of this trial later this …

Varian

The Radiosurgery Society® Announces the Newest Members of its RSS Sponsorship Alliance | PRWeb | 4/29/2020

… to advancing the science and clinical practice of radiosurgery, today announced that NYU Langone Hospitals and The University of Texas MD Anderson Cancer Center have joined the organization’s growing membership in its RSS Sponsorship Alliance … each. Current corporate and network sponsors include Accuray, Elekta, Masep, Varian, ViewRay and Zap Surgical Systems. PetCure Oncology is the RSS’s inaugural Network Affiliate sponsor. More information on the RSS Sponsorship Alliance and its associated …

Adaptimmune

Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020 | Globe Newswire | 4/29/2020

April 29, 2020 08:00 ET Source: Adaptimmune Therapeutics plc - The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in cell therapy to … Tumors” will be presented by Dr. David Hong of the MD Anderson Cancer Center A trial-in-progress poster summarizing the ongoing Phase 2 SPEARHEAD-1 trial design will be presented by Dr. Dejka Araujo …

Weill Cornell Medicine

Lymphoma Research Foundation to Host Nationwide Virtual Rally | PRWeb | 4/28/2020

… MD Anderson Cancer Center, Julie Vose, MD, MBA from the University of Nebraska Medical Center, Thomas Habermann, MD from the University of Nebraska Medical Center, and Peter Martin, MD from Weill Cornell Medicine. LRF will also honor the four The Future’s So Bright Award Winners for their outstanding efforts to improve the lives of people diagnosed with lymphoma. The award recipients are Cindy Ngo, Maricel Del Sol, Alex Weed, and …

Iovance Biotherapeutics

AACR: Iovance details early responses to TIL cell therapy in lung cancer | FierceBiotech | 4/27/2020

On April 14, shares of Iovance Biotherapeutics jumped 17%, thanks to three magic words in the title of an abstract the company said will be presented at this week’s virtual meeting of the American Association … the product. Iovance teamed up with the University of Texas MD Anderson Cancer Center in 2017 to study TILs in several tumor types. And in January of this year, it licensed technology from Cellectis that …

NCI

PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer | Globe Newswire | 6/22/2020

NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020 June 22, 2020 08:30 ET Source: PDS Biotechnology Corporation FLORHAM PARK, N.J., June 22, 2020 (GLOBE NEWSWIRE) – PDS Biotechnology Corporation … the National Cancer Institute (NCI), and The University of Texas MD Anderson Cancer Center, PDS Biotech is conducting additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer respectively. Forward Looking …

Goldman Sachs

Edited Transcript of MCRB earnings conference call or presentation 7-May-20 12:30pm GMT | Yahoo News | 6/7/2020

… Reid Zelin Canaccord Genuity Corp., Research Division - Associate Matthew Cornell Biegler Oppenheimer & Co. Inc., Research Division - Associate Melissa J. Hilton Goldman Sachs Group Inc., Research Division - Research Analyst Vernon Tolentino Bernardino H.C. Wainwright & Co, LLC … In collaboration with the Parker Institute for Cancer Immunotherapy and MD Anderson Cancer Center, we continue to enroll a randomized, placebo-controlled Phase Ib study of SER-401. The study was designed to enroll 30 …

HealthCare Partners

Legion Healthcare Partners adds Expert in Immuno-RT to its Scientific Advisory Board | Yahoo News | 3/18/2020

Legion Healthcare Partners is pleased to announce the addition of span class=”xn-person” James Welsh /span , MD to its Scientific Advisory Board. Dr. Welsh is an Associate Professor of Radiation Oncology at The span class=”xn-org” University of Texas /span MD Anderson Cancer Center. Dr. Welsh is focused on enhancing the effects of immunotherapy through its rational combination with radiation. Dr. Welsh oversees the immunotherapy lab while also …

Industry Ventures

Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program | Globe Newswire | 10/28/2019

… HOUSTON, Oct. 28, 2019 (GLOBE NEWSWIRE) – Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP ), and The University of Texas MD Anderson Cancer Center today announced a new research and development agreement relating to Ziopharm’s … Prat, Ph.D., J.D. , senior vice president for Research Administration and Industry Ventures at MD Anderson. “We are pleased to be working with Ziopharm to advance a new generation of cell therapies, and we are hopeful …

Remeditex Ventures

Soliton Announces $6.25 Million Private Placement | PR Newswire | 10/10/2019

MD Anderson Cancer Center (“MD Anderson”), today announced that it has entered into definitive agreements with certain institutional and accredited investors to raise aggregate gross proceeds of approximately $6.25 million through the private placement of its equity securities. The financing was led by Remeditex Ventures, LLC, the Company’s largest shareholder, which agreed to purchase $2.0 million of the securities in the private placement. Soliton will sell 485,250 shares of the …

B Capital Group

Notable Nabs $40M to Expand Drug Discovery Platform for Personalized Oncology | HIT Consultant | 7/17/2019

… rapidly advances cancer drug development has raised $40M in Series B funding. The Series B round is co-led by B Capital Group and LifeForce Capital. LifeForce is a returning investor, joined by new investors … validated in multiple independent clinical studies conducted by Stanford University, MD Anderson Cancer Center, University of California San Francisco, Rady Children’s Hospital, and Texas Children’s Hospital, among others …

LifeForce Capital

Notable Nabs $40M to Expand Drug Discovery Platform for Personalized Oncology | HIT Consultant | 7/17/2019

… development has raised $40M in Series B funding. The Series B round is co-led by B Capital Group and LifeForce Capital. LifeForce is a returning investor, joined by new investors B Capital and Industry … validated in multiple independent clinical studies conducted by Stanford University, MD Anderson Cancer Center, University of California San Francisco, Rady Children’s Hospital, and Texas Children’s Hospital, among others …

Maxim Group

Soliton Announces $9.45 Million Private Placement | Markets Insider | Business Insider | 6/17/2019

… medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has entered into definitive agreements … as lead placement agent for the transaction. Boustead Securities and Maxim Group are acting as co-placement agents. This press release does not constitute an offer to sell or the solicitation of an offer to …

SunTrust Robinson Humphrey

Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/22/2019

… Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Maurice Raycroft - Jefferies Jim Birchenough - Wells Fargo Peter Lawson - SunTrust Robinson Humphrey Daina Graybosch - SVB Leerink Yale Jen - Laidlaw Company Gregory Gin Thank you … An example of these efforts is our work with the MD Anderson Cancer Center and their investigator-sponsored study directed towards development of an off-the-shelf adoptive immunotherapy comprised of AFM13 premixed with MD …

ARCH Venture Partners

After beefy funding rounds, exosome-focused Codiak guns for $86M IPO | FierceMedicalDevices | 4/30/2019

… D chief Doug Williams and $31 million in venture funding. A $61 million series B followed just months later as Arch Venture Partners, Flagship Ventures and other investors comfortable placing big bets on biotech piled … preclinical antitumor activity. Back in the summer of 2017, an MD Anderson Cancer Center team including Raghu Kalluri, M.D., Ph.D., who was an early collaborator with Codiak, showed uptake of RNAi-laden exosomes by pancreatic …

Leukemia & Lymphoma Society

Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® (ruxolitinib) in Patients with Polycythemia Vera | Business Wire | 12/10/2017

… intolerant of hydroxyurea,” said Srdan Verstovsek, M.D., Ph.D., medical oncologist and professor, Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas. About the RESPONSE Trial RESPONSE is an ongoing, global … up from the RESPONSE trial. Haematologica. 2016;101(7):821-829. Leukemia & Lymphoma Society. “Polycythemia Vera Facts.” Available at: https://www.lls.org/sites/default/files/file_assets/FS13_PolycythemiaVera_FactSheet_final5.1.15.pdf. Accessed November 2015 . Marchioli R …

Mayfield Fund

Mission Bio Adds to Executive Team to Move Precision Medicine Forward | Business Wire | 11/3/2017

… follow on last month’s announcement of a $10 million Series A funding round led by Silicon Valley venture capital firm Mayfield Fund. “It’s a privilege to bring such experienced talent onto our executive team,” said … may impact disease progression and treatment. Early access customers from MD Anderson Cancer Center and Stanford University School of Medicine report promising data in the use of Tapestri to support their research of acute myeloid …

UT Southwestern Medical Center

University of Texas System and Medline to Enhance Supply Chain Strategy and Outcomes | PR Newswire | 6/29/2020

NORTHFIELD, Ill. Medline today announced a $120 million annual partnership with The University of Texas System Supply Chain Alliance . This award provides distribution services to the UT System’s three acute care institutions: UT Southwestern Medical Center in Dallas , UT MD Anderson Cancer Center in Houston , and UT Medical Branch in Galveston. Prior to choosing Medline as their MedSurg Distributor, the three institutions were using different distributors. Now, their distribution is …

University of Texas System

University of Texas System and Medline to Enhance Supply Chain Strategy and Outcomes | PR Newswire | 6/29/2020

NORTHFIELD, Ill. Medline today announced a $120 million annual partnership with The University of Texas System Supply Chain Alliance . This award provides distribution services to the UT System’s three acute care institutions: UT Southwestern Medical Center in Dallas , UT MD Anderson Cancer Center in Houston , and UT Medical Branch in Galveston. Prior to choosing Medline as their MedSurg Distributor, the three institutions were using different distributors. Now, their distribution is …

Harvard Medical School

ASH Announces 2020 Honorific Award Recipients | PR Newswire | 6/23/2020

… Coulter Award for Lifetime Achievement in Hematology Ari Melnick , MD, Weill Cornell Medicine Courtney DiNardo , MD, The University of Texas MD Anderson Cancer Center Ernest Beutler Lecture and Prize Adolfo Ferrando , MD, PhD, Columbia University … Awards Edward J. Benz, Jr. , MD, Dana-Farber Cancer Institute, Harvard Medical School Leadership in Promoting Diversity The awards will be presented during the 62nd ASH Annual Meeting, December 5-8, 2020 . The American Society of …

Dana Farber Cancer Institute

ASH Announces 2020 Honorific Award Recipients | PR Newswire | 6/23/2020

… Honorific Awards recipients are: Mohandas Narla, DSc, New York Blood Center Wallace H. Coulter Award for Lifetime Achievement in Hematology Ari Melnick , MD, Weill Cornell Medicine Courtney DiNardo , MD, The University of Texas MD Anderson Cancer Center Ernest Beutler Lecture and Prize Adolfo Ferrando , MD, PhD, Columbia University Genetics William Dameshek Prize Toshio Suda , MD, PhD, National University of Singapore and the International Research Center for Medical Sciences, Kumamoto University …

Memorial Sloan Kettering Cancer Center

Loki Therapeutics Forms Scientific Advisory Board to Advance Development of “Childhood Vaccination”-Based Cancer Therapeutics | PR Newswire | 6/15/2020

… the formation of its Scientific Advisory Board (SAB), and the appointment of several prominent members, including Eileen O’Reilly , MD, of Memorial Sloan Kettering Cancer Center; Alan Forsythe , Ph.D., of Forsythe and Bear, LLC, a biostatistical … with a year-long fellowship at the University of Texas MD Anderson Cancer Center, after which he trained at the University of Alabama-Birmingham Hospital. While there, he completed an internship and residency in General …

Memorial Sloan Kettering

Loki Therapeutics Forms Scientific Advisory Board to Advance Development of “Childhood Vaccination”-Based Cancer Therapeutics | PR Newswire | 6/15/2020

… the formation of its Scientific Advisory Board (SAB), and the appointment of several prominent members, including Eileen O’Reilly , MD, of Memorial Sloan Kettering Cancer Center; Alan Forsythe , Ph.D., of Forsythe and Bear, LLC, a biostatistical … with a year-long fellowship at the University of Texas MD Anderson Cancer Center, after which he trained at the University of Alabama-Birmingham Hospital. While there, he completed an internship and residency in General …

Montefiore Medical Center

Loki Therapeutics Forms Scientific Advisory Board to Advance Development of “Childhood Vaccination”-Based Cancer Therapeutics | PR Newswire | 6/15/2020

… Forsythe and Bear, LLC, a biostatistical consulting firm; and John McAuliffe , MD, Ph.D., F.A.C.S., and Jennifer Chuy , MD, both of Montefiore Medical Center/Albert Einstein College of Medicine. Drs. O’Reilly, Forsythe, McAuliffe and Chuy will … with a year-long fellowship at the University of Texas MD Anderson Cancer Center, after which he trained at the University of Alabama-Birmingham Hospital. While there, he completed an internship and residency in General …

Vanderbilt University Medical Center

Genelux Announces Formation of Clinical Advisory Board on Gynecologic Cancers | PR Newswire | 6/4/2020

… AdventHealth, Orlando . Dr. Holloway has authored or coauthored more than 100 peer-reviewed articles. Dr. Holloway completed medical school at Vanderbilt University Medical Center, residency at University of Alabama, Birmingham , and fellowship at Georgetown University … Center, and gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. He served as Professor and Ann Rife Chair in Gynecology at University of Texas , M.D. Anderson Cancer Center and Executive Director …

University Medical Center

Genelux Announces Formation of Clinical Advisory Board on Gynecologic Cancers | PR Newswire | 6/4/2020

… Orlando . Dr. Holloway has authored or coauthored more than 100 peer-reviewed articles. Dr. Holloway completed medical school at Vanderbilt University Medical Center, residency at University of Alabama, Birmingham , and fellowship at Georgetown University Hospital … Center, and gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. He served as Professor and Ann Rife Chair in Gynecology at University of Texas , M.D. Anderson Cancer Center and Executive Director …

Northwell Health

Northwell Health Cancer Institute hires 4 new executives | Becker’s Hospital Review | 6/2/2020

Northwell Health Cancer Institute hires 4 new executives Kelly Gooch - Print Email New Hyde Park, N.Y.-based Northwell Health said it has appointed four executives at its cancer institute to bolster cancer care management, research … professor and division head of Houston-based University of Texas MD Anderson Cancer Center’s radiation oncology department. Dr. Karpeh, who specializes in the surgical management of gastrointestinal cancers, will direct programs at Northwell Health’s Huntington …

Geisinger

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

… of patient satisfaction. Here are the 18 hospitals that received a 2020 MAP award, along with five physician practice winners: Geisinger (Danville, Pa.) Presbyterian Healthcare Services (Albuquerque, N.M.) Saint Francis Health System (Tulsa, Okla.) Bon … St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners …

Regional Medical Center

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners: ENT & Allergy Associates (Tarrytown, N.Y.) Graves-Gilbert Clinic (Bowling Green, Ky.) Privia Medical Group (Arlington, Va.) St. Elizabeth Physicians (Erlanger, Ky.) Virginia Eye Institute (Richmond, Va.) View the full press release here . More articles on healthcare finance …

Saint Francis Health System

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

Saint Francis Health System (Tulsa, Okla.) Bon Secours Mercy Health (Cincinnati) Cape Cod Healthcare (Hyannis, Mass.) OhioHealth (Columbus) Spectrum Health (Grand Rapids, Mich.) St. Elizabeth Healthcare (Edgewood, Ky.) CHRISTUS Shreveport-Bossier Health System (Highland; Shreveport, La.) Dignity Health Mercy General Hospital (Sacramento, Calif.) Liberty (Mo.) Hospital Norton Healthcare, Norton Brownsboro Hospital (Louisville, Ky.) Princeton Baptist Medical Center (Birmingham, Ala.) St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD …

Mercy

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

Mercy Health (Cincinnati) Cape Cod Healthcare (Hyannis, Mass.) OhioHealth (Columbus) Spectrum Health (Grand Rapids, Mich.) St. Elizabeth Healthcare (Edgewood, Ky.) CHRISTUS Shreveport-Bossier Health System (Highland; Shreveport, La.) Dignity Health Mercy General Hospital (Sacramento, Calif.) Liberty (Mo.) Hospital Norton Healthcare, Norton Brownsboro Hospital (Louisville, Ky.) Princeton Baptist Medical Center (Birmingham, Ala.) St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y …

Unity Hospital

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners: ENT & Allergy Associates (Tarrytown, N.Y.) Graves-Gilbert Clinic (Bowling Green, Ky.) Privia Medical Group (Arlington, Va.) St. Elizabeth Physicians (Erlanger, Ky.) Virginia Eye Institute (Richmond, Va.) View the full press release here . More articles on healthcare finance …

Spectrum Health

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

Spectrum Health (Grand Rapids, Mich.) St. Elizabeth Healthcare (Edgewood, Ky.) CHRISTUS Shreveport-Bossier Health System (Highland; Shreveport, La.) Dignity Health Mercy General Hospital (Sacramento, Calif.) Liberty (Mo.) Hospital Norton Healthcare, Norton Brownsboro Hospital (Louisville, Ky.) Princeton Baptist Medical Center (Birmingham, Ala.) St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional …

OhioHealth

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

OhioHealth (Columbus) Spectrum Health (Grand Rapids, Mich.) St. Elizabeth Healthcare (Edgewood, Ky.) CHRISTUS Shreveport-Bossier Health System (Highland; Shreveport, La.) Dignity Health Mercy General Hospital (Sacramento, Calif.) Liberty (Mo.) Hospital Norton Healthcare, Norton Brownsboro Hospital (Louisville, Ky.) Princeton Baptist Medical Center (Birmingham, Ala.) St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa …

Bon Secours Mercy Health

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

Bon Secours Mercy Health (Cincinnati) Cape Cod Healthcare (Hyannis, Mass.) OhioHealth (Columbus) Spectrum Health (Grand Rapids, Mich.) St. Elizabeth Healthcare (Edgewood, Ky.) CHRISTUS Shreveport-Bossier Health System (Highland; Shreveport, La.) Dignity Health Mercy General Hospital (Sacramento, Calif.) Liberty (Mo.) Hospital Norton Healthcare, Norton Brownsboro Hospital (Louisville, Ky.) Princeton Baptist Medical Center (Birmingham, Ala.) St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital …

Baptist Medical Center

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

Baptist Medical Center (Birmingham, Ala.) St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners: ENT & Allergy Associates (Tarrytown, N.Y.) Graves-Gilbert Clinic (Bowling Green, Ky.) Privia Medical Group (Arlington, Va.) St. Elizabeth Physicians (Erlanger, Ky.) Virginia Eye Institute (Richmond, Va.) View the full press …

Huntington Hospital

Northwell Health Cancer Institute hires 4 new executives | Becker’s Hospital Review | 6/2/2020

… MD Anderson Cancer Center’s radiation oncology department. Dr. Karpeh, who specializes in the surgical management of gastrointestinal cancers, will direct programs at Northwell Health’s Huntington Hospital, Southside Hospital in Bay Shore, N.Y., and Peconic Bay Medical Center in Riverhead, N.Y., Northwell Health said. Dr. Karpeh joined Northwell Health in April to help amid the COVID-19 pandemic after serving as surgeon-in-chief at Hackensack (N.J.) University Medical Center …

St. Mary Medical Center

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners: ENT & Allergy Associates (Tarrytown, N.Y.) Graves-Gilbert Clinic (Bowling Green, Ky.) Privia Medical Group (Arlington, Va.) St. Elizabeth Physicians (Erlanger, Ky.) Virginia Eye Institute (Richmond, Va.) View the full press release here . More articles on …

Presbyterian Healthcare Services

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

… Here are the 18 hospitals that received a 2020 MAP award, along with five physician practice winners: Geisinger (Danville, Pa.) Presbyterian Healthcare Services (Albuquerque, N.M.) Saint Francis Health System (Tulsa, Okla.) Bon Secours Mercy Health … St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners …

Dignity Health

18 hospitals with high-performing revenue cycles | Becker’s Hospital Review | 6/2/2020

Dignity Health Mercy General Hospital (Sacramento, Calif.) Liberty (Mo.) Hospital Norton Healthcare, Norton Brownsboro Hospital (Louisville, Ky.) Princeton Baptist Medical Center (Birmingham, Ala.) St. Mary Medical Center (Langhorne, Pa.) The University of Texas MD Anderson Cancer Center (Houston) Unity Hospital (Rochester, N.Y.) Buena Vista Regional Medical Center (Storm Lake, Iowa) Greater Regional Health (Creston, Iowa) Physician practice winners: ENT & Allergy Associates (Tarrytown, N.Y.) Graves-Gilbert Clinic (Bowling Green, Ky.) Privia …

Peconic Bay Medical Center

Northwell Health Cancer Institute hires 4 new executives | Becker’s Hospital Review | 6/2/2020

… MD Anderson Cancer Center’s radiation oncology department. Dr. Karpeh, who specializes in the surgical management of gastrointestinal cancers, will direct programs at Northwell Health’s Huntington Hospital, Southside Hospital in Bay Shore, N.Y., and Peconic Bay Medical Center in Riverhead, N.Y., Northwell Health said. Dr. Karpeh joined Northwell Health in April to help amid the COVID-19 pandemic after serving as surgeon-in-chief at Hackensack (N.J.) University Medical Center …

NYU Langone Health

Primary care practices fear they may not survive the pandemic | Crain’s New York Business | 6/1/2020

… survey . And even large practices have noted the high costs of obtaining PPE . Shelley and her colleagues are working with NYU Langone Health as well as the city Health Department on the research. NYC Reach … division head of radiation oncology at the University of Texas MD Anderson Cancer Center. MEDICAL EDUCATION: Iona College in New Rochelle said last week it has created a bachelor of science degree program in nursing …

Cigna

Retail makes its case, telehealth and voice tech dominate: 6 takeaways from HLTH19 | Healthcare Dive | 11/6/2019

… Nigrin, SVP and CIO at Boston Children’s Hospital. “It starts with our organizational strategy,” agreed Rebecca Kaul, VP at the MD Anderson Cancer Center. An attractive startup presents “something that really drives change,” she said … to invest in that could provide value down the road. Cigna Ventures, which recently invested in precision medicine company GNS Healthcare, looks for new tools across the areas of insight and analytics, digital health and …

20 healthcare CEOs with best employee reviews on Glassdoor | Becker’s Hospital Review | 6/19/2019

… 29: Steven Bilt (Smile Brands) No. 44: Michael Dowling (Northwell Health in New Hyde Park, N.Y.) No. 47: Peter Pisters (MD Anderson Cancer Center in Houston) No. 49: Bob Quattrocchi (Northside Hospital in Atlanta) No … No. 95: Pat Bauer (Heartland Dental) No. 96: David Cordani (Cigna) No. 99: David Baiada (Bayada Home Healthcare) More articles on rankings and ratings …

Humana

7 can’t-miss panels at HLTH19 | Healthcare Dive | 10/24/2019

… Rx ), Jay Bhatt, SVP and chief medical officer of the American Hospital Association, and Rebecca Kaul, VP and CIO of MD Anderson Cancer Center. Intermountain recently started a new company that consults with payers and … health and benefits company Accolade, which works with companies like Humana, Independence Blue Cross, Teladoc and Lowes on improving health outcomes …

Global Genitourinary Partnering Deal Trends, Players and Financials Directory 2014-2019 | PR Newswire | 10/24/2019

… of Canada Hainan Sihuan Pharmaceutical Hancock Jaffe Laboratories Harvard Stem Cell Institute Healthy.io Helix BioPharma HemoCleanse Hitachi Medical Systems Europe Humana Hydra Biosciences HydroCision Icahn School of Medicine at Mount Sinai Idera Pharmaceuticals IDIBELL ImpediMed … Mar Cor Purification Mariel Therapeutics Massachusetts General Hospital Mayo Clinic MD Anderson Cancer Center MedCom MediBeacon MediGene Medinova Medipal Holdings Medison Pharma Medline Industries Medpace Medtronic Meiji Seika Melinta Therapeutics Memorial Sloan Kettering Cancer Center …

UnitedHealthcare

Judge rips insurance company for ‘immoral, barbaric’ cancer denials - CNN | 5/16/2019

CNN) A federal judge blasted UnitedHealthcare last month for its “immoral and barbaric” denials of treatment for cancer patients. He made the comments in recusing himself from hearing a class-action lawsuit because of his … UnitedHealthcare refused to pay for his proton beam radiation from MD Anderson Cancer Center. “Only upon threat of litigation did UnitedHealthcare agree to reimburse him,” Scola wrote. In scathing ruling, judge rips insurer for putting …

Judge rips insurance company for ‘immoral, barbaric’ cancer denials - CNN | 5/16/2019

CNN) A federal judge blasted UnitedHealthcare last month for its “immoral and barbaric” denials of treatment for cancer patients. He made the comments in recusing himself from hearing a class-action lawsuit because of his … UnitedHealthcare refused to pay for his proton beam radiation from MD Anderson Cancer Center. “Only upon threat of litigation did UnitedHealthcare agree to reimburse him,” Scola wrote. In scathing ruling, judge rips insurer for putting …

Roberta Schwartz

Houston hospitals grapple with bed, crucial medicine shortages amid COVID-19 spike | Becker’s Hospital Review | 7/2/2020

… appointments. “To tell you the truth, what worries me is not this week, where we’re still kind of handling it,” Roberta Schwartz, PhD, Houston Methodist’s chief innovation officer who is leading efforts to expand the … obtained by NBC News and ProPublica . The University of Texas MD Anderson Cancer Center also alerted employees that it would start admitting cancer patients with COVID-19 from public hospitals in the city. To view …

Thomas McGinn

Watch: From nose to toe, the Covid-19 virus attacks like no other ‘respiratory’ infection | STAT | 6/26/2020

… this coronavirus “has such a diversity of effects on so many different organs, it keeps us up at night,” said Thomas McGinn, deputy physician in chief at Northwell Health and director of the Feinstein Institutes … cell types has been well-known,” said Anirban Maitra of MD Anderson Cancer Center, who led a study mapping the receptor in cells of the GI tract. (Maitra is an expert in pancreatic cancer and …

NgocDiep Le

NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors | Business Wire | 6/25/2020

… clinical-stage T cell-focused biopharmaceutical company, today announced the first patient has been dosed at The University of Texas MD Anderson Cancer Center in the Phase 1b/2a clinical trial of NT-I7 (efineptakin … for the treatment of patients with advanced solid tumors,” said NgocDiep Le, M.D., Ph.D., Executive VP and Chief Medical Officer of NeoImmuneTech. “We will investigate clinically NT-I7’s potential to augment the already proven …

Fred Hutchinson

ASH Announces 2020 Honorific Award Recipients | PR Newswire | 6/23/2020

… for their outstanding contributions to hematology through patient care, research, and mentorship,” said ASH President Stephanie Lee , MD, MPH, of Fred Hutchinson Cancer Research Center. “Each year the Society honors individuals who represent some of … Weill Cornell Medicine Courtney DiNardo , MD, The University of Texas MD Anderson Cancer Center Ernest Beutler Lecture and Prize Adolfo Ferrando , MD, PhD, Columbia University Genetics William Dameshek Prize Toshio Suda , MD, PhD, National University …

Adi Hoess

Affimed Reports First Quarter 2020 Financial Results and Operational Progress | Globe Newswire | 6/23/2020

… on the REDIRECT monotherapy study in pTCL as well as on the AFM13 combination with cbNk investigator sponsored study at MD Anderson Cancer Center in CD30-positive T cell lymphoma Management: Appointed Angus Smith as … in close collaboration with our investigators and partners,” said Dr. Adi Hoess, CEO of Affimed. “We have strengthened the management team with the recent hiring of Angus Smith as CFO, which nicely complements the additions …

Saiid Zarrabian

DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II | PR Newswire | 6/22/2020

… 083’s new drug application (NDA) submission and registration. Dr. John de Groot , Chairman of the Department of Oncology at MD Anderson Cancer Center and planned Principal Investigator for the VAL-083 arm of the … adjuvant group as of the relevant data cut-off dates. Saiid Zarrabian , CEO of DelMar Pharmaceuticals, added, “ We continue to be encouraged with the interim outcomes for both of our ongoing Phase 2 trials of …

John de Groot

DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II | PR Newswire | 6/22/2020

John de Groot , Chairman of the Department of Oncology at MD Anderson Cancer Center and planned Principal Investigator for the VAL-083 arm of the GCAR GBM AGILE registration study, noted, “These data continue to demonstrate an improvement over the historical outcomes of standard therapy and validate VAL-083’s inclusion in a more robust setting as part of the GBM AGILE study. In MD Anderson’s Glioblastoma Moon Shots Program …

Michael Yu

Innovent Announces The Stock Exchange of Hong Kong Limited Approved the “B” Marker Removal from the Company’s Stock Symbol in the HKEX | PR Newswire | 6/22/2020

… look forward to the possibility to be considered for inclusion in the Heng Seng indices in the future ,” said Dr. Michael Yu , Founder, Chairman and CEO of Innovent. “Innovent is committed to continuously advancing our … also entered into strategic collaborations with Eli Lilly, Adimab , Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with all relevant parties to help advance China’s biopharmaceutical industry, improve drug …

Susan Gilchrist

Health Highlights: June 19, 2020 | U.S. News & World Report | 6/19/2020

… Susan Gilchrist, associate professor of clinical cancer prevention, MD Anderson Cancer Center, University of Texas, CNN reported. However, she added that replacing at least 30 minutes of sitting with either light, moderate or vigorous physical activity may reduce the risk. Journal Should Retract Mask Study: Scientists A study on the use of masks to protect against the new coronavirus should be retracted by the journal Proceedings of the National Academy …

Don Rucker

NCCN Policy Summit Explores 21st Century Cures Act and the Impact of Health Information Technology | Yahoo News | 6/10/2020

… Administration (FDA) held a fireside chat on clinical trials, data, and how real world evidence is changing the research landscape. Don Rucker , MD, MBA, MS , National Coordinator for Health Information Technology , Office of the National … NCCN Board Chair & Breast Medical Oncologist , The University of Texas MD Anderson Cancer Center . Drs. Allen and Walters presented recommendations for future policy improvements according to an NCCN working group of multidisciplinary experts from across …

Clifford Goodman

NCCN Policy Summit Explores 21st Century Cures Act and the Impact of Health Information Technology | Yahoo News | 6/10/2020

… The need for improving patient access to medical records was also a key theme for the panel discussion moderated by Clifford Goodman , PhD, Senior Vice President of The Lewin Group and featuring Jenny Ahlstrom , Founder … NCCN Board Chair & Breast Medical Oncologist , The University of Texas MD Anderson Cancer Center . Drs. Allen and Walters presented recommendations for future policy improvements according to an NCCN working group of multidisciplinary experts from across …

Robert L. Coleman

Genelux Announces Formation of Clinical Advisory Board on Gynecologic Cancers | PR Newswire | 6/4/2020

… completed medical school at Vanderbilt University Medical Center, residency at University of Alabama, Birmingham , and fellowship at Georgetown University Hospital. Robert L. Coleman , MD – Gynecologic Oncology, Chief Scientific Officer, US Oncology Research , The Woodlands, Texas … Center, and gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. He served as Professor and Ann Rife Chair in Gynecology at University of Texas , M.D. Anderson Cancer Center and Executive Director …

Mario Sznol

Online Video Education Series from SITC and PlatformQ Health to Better Equip HCPs Managing Cancer Patients Undergoing Immunotherapy | PRWeb | 6/3/2020

… tumors. Online education is especially important now, when travel to in-person conferences or workshops may not be an option. - Mario Sznol, MD, SITC President BOSTON (PRWEB) June 03, 2020 PlatformQ Health Education (PQHE) and … Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. Dr. Herbst recently presented findings from a study showing profound benefits with targeted therapy for patients with early stage NSCLC at …

Kelly Gooch

Northwell Health Cancer Institute hires 4 new executives | Becker’s Hospital Review | 6/2/2020

Northwell Health Cancer Institute hires 4 new executives Kelly Gooch - Print Email New Hyde Park, N.Y.-based Northwell Health said it has appointed four executives at its cancer institute to bolster cancer care management, research … professor and division head of Houston-based University of Texas MD Anderson Cancer Center’s radiation oncology department. Dr. Karpeh, who specializes in the surgical management of gastrointestinal cancers, will direct programs at Northwell Health’s Huntington …

Joseph J. Fifer

23 Winners Receive the 2020 MAP Award for High Performance in Revenue Cycle | Globe Newswire | 6/1/2020

… Joseph J. Fifer, FHFMA, CPA, said, “During a time when many consumers have lost jobs and health insurance coverage as a result of the COVID-19 pandemic, the consumer-friendly business practices exemplified by our 2020 winners are more important than ever.” Upon being notified they had received the award, The University of Texas MD Anderson Cancer Center Vice President, Revenue Cycle and Treasurer Brad Gibson said, “We are honored …

Ned Sharpless

NIAID Council Minutes - January 27, 2020 | National Institutes of Health | 5/28/2020

… MD Anderson Cancer Center. He takes over for Acting Commissioner Dr. Ned Sharpless, who returns to his previous position as director of the National Cancer Institute. Dr. Joshua Denny has been selected as CEO of the “All of Us” Research Program. As CEO, he will oversee NIH’s efforts to build one of the most comprehensive precision medicine research platforms in the world in partnership with a diverse network of awardees …

Stephen Hahn

NIAID Council Minutes - January 27, 2020 | National Institutes of Health | 5/28/2020

Stephen Hahn was sworn in as the 24 th commissioner of the Food and Drug Administration. Before joining FDA, Dr. Hahn served as the chief medical executive at the University of Texas, MD Anderson Cancer Center. He takes over for Acting Commissioner Dr. Ned Sharpless, who returns to his previous position as director of the National Cancer Institute. Dr. Joshua Denny has been selected as CEO of the “All of …

John Theurer

Hackensack Meridian Health Observational Study Demonstrates Lack of Efficacy of Hydroxychloroquine Among Hospitalized COVID-19 Patients But Finds First Treatment (tocilizumab) to Improve Survival | PR Newswire | 5/27/2020

… in randomized trials – and Hackensack Meridian Health is participating in those randomized trials as well.” The outcomes division of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center, under the leadership of Dr … Berry , Ph.D., professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center and his statistical team at Berry Consultants. “Being at the epicenter with a large volume of patients and having the benefit …

Kate Wilson

Impacts of Genesurance Considerations on Genetic Counselors’ Practice and Attitudes - PubMed | National Institutes of Health | 5/21/2020

Impacts of Genesurance Considerations on Genetic Counselors’ Practice and Attitudes Emily Thoreson et al. J Genet Couns . 2020 doi: 10.1002/jgc4.1291. Online ahead of print. Authors Emily Thoreson 1 2 , Lauren Murphy 1 3 , Jennifer Lemons 1 4 , Laura Farach 1 4 , Kate Wilson 5 , Ashley Woodson 1 6 , Chelsea Wagner 1 3 Affiliations 1 University of Texas Genetic Counseling Program, University of Texas MD Anderson Cancer Center UTHealth Graduate …

Helen Diller

OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424 | PR Newswire | 5/20/2020

… negative breast cancer (TNBC) at high risk for recurrence. Presenter: Hope S. Rugo, MD, FASCO University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA Session Title: Breast Cancer—Local/Regional … Presenter: Apostolia Maria Tsimberidou, MD, Ph.D, The University of Texas MD Anderson Cancer Center, Houston, TX Session Date and Time: Friday, May 29, 2020. 8:00 a.m. – 11:00 a.m. Eastern Time https://meetinglibrary.asco.org/record/191854/abstract …

Hagop Kantarjian

SELLAS Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update | Globe Newswire | 5/14/2020

… Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, and Principal Investigator at MD Anderson for the multi-center Phase 3 REGAL study and Chair of the REGAL Steering Committee; Dr. Javier Pinilla-Ibarz, MD, PhD, Director of Immunotherapy for Malignant Hematology at the H. Lee Moffitt Cancer Center and member of the SELLAS Scientific Advisory Board; and Dr …

David Jaffray

Becker’s Health IT + Revenue Cycle 2020: 4 Questions with Rebecca Kaul, Chief Innovation Officer & David Jaffray, Chief Technology and Digital Officer for The University of Texas MD Anderson Cancer Center | Becker’s Hospital Review | 5/6/2020

Rebecca Kaul serves as Chief Innovation Officer and Vice President for The University of Texas MD Anderson Cancer Center. David Jaffray, PhD, serves as Chief Technology and Digital Officer for The University of Texas MD Anderson Cancer Center. On October 14th, Rebecca will serve on the keynote panel “Balancing Innovation and Data Privacy” and on October 15th, Dr. Jaffray will serve on the panel “Key Innovations in Telehealth, Mobile Health …

Min Yan

First Quantitative Assessment of Treatments for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin (BCG) Therapy Published in European Urology Oncology | PR Newswire | 5/6/2020

… MD Anderson Cancer Center. The study has already been the focus of clinical video lectures, such as one given to the UroToday Journal Club . Analysis Group Vice President Min Yang and Associate Mihaela Georgieva supported a systematic literature review of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) from January 2007 through June 2019 , and abstracts and presentations from major conference proceedings. Data for single-arm trials …

Amit Kumar

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid Biopsy Technology | PR Newswire | 4/23/2020

… AI to identify tumor-bearing patients. The journal article, co-authored by Anixa with collaborators from the Wistar Institute, the MD Anderson Cancer Center at Cooper and the Cooper Medical School of Rowan University and … which surgery is not required and a biopsy is unnecessary. Amit Kumar , Ph.D., Chief Executive of Anixa and the study’s senior author, stated, “The Anixa team is excited by the publication of our scientific paper …

Bruno Mars

Dozens of Health Care Workers Sing Sweet Tribute | WebMD | 4/23/2020

The employee choir at the University of Texas MD Anderson Cancer Center sang a cover of “Count on Me” by Bruno Mars from nearly 30 locations. “Social distancing isn’t stopping our employee choir from lifting spirits during the COVID-19 pandemic,” the hospital shared on Facebook “Music has been said to have a healing effect mentally, emotionally, and psychologically,” a rep for the hospital told CBS News. “The song ‘Count …